The Biomolecular Resource Laboratory (BRL) is a heavily used core service laboratory of the Comprehensive Cancer Center that supported the research laboratory activities of 41 Cancer Center members during fiscal year 2005. The BRL provides strategically important analytical services to Center members for 1) characterization of DMA, peptides, proteins and 2) identification and quantification of lipids, proteins, and peptides. These services include five different types of mass spectrometry for analysis of proteins, peptides and lipids, automated DNA sequence analysis, synthesis of RNA and DNA oligonucleotides, purification of peptides and proteins, and chemical synthesis of peptides. The BRL analyzed more than 14,000 samples during the reporting period. DNA sequence analysis (7924 samples) and mass spectrometry (6403 samples) were the most heavily used core services in the BRL. The protein/peptide and DNA chemical services accounted for an additional 956 samples. Laboratories of Cancer Center members received 49% of the services performed in the BRL during fiscal year 2005. The BRL has expanded significantly since the last review. Mass spectrometry services have been added to meet the significant needs of Cancer Center members for metabolomics and proteomics. During the last funding period, three new mass spectrometers were added to the facility. These included two Bruker mass spectrometers (an Autoflex MALDI-TOF and an Esquire HCT ion trap) and a Waters/Micromass Quadrupole Time-of-flight (Q-TOF) mass spectrometer, specifically to enhance the study of proteins and lipids. Dr. Michael Thomas, a leading expert in the analysis of lipids and lipid metabolites by mass spectrometry, has joined the laboratory as a co-director with Dr. Mark Lively. The addition of Dr. Thomas, and his staff and instrumentation, has enhanced the ability of the BRL to meet the needs of the Cancer Center program members in the especially important areas of proteomics and metabolomics. Together, Drs. Lively and Thomas provide significant expertise in biochemistry of proteins and DNA, mass spectrometry, and analytical methods to enhance and promote cancer research in the CCCWFU.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA012197-36
Application #
8213159
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-02-01
Budget End
2012-01-31
Support Year
36
Fiscal Year
2011
Total Cost
$155,181
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Feliz-Mosquea, Yismeilin R; Christensen, Ashley A; Wilson, Adam S et al. (2018) Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy. Breast Cancer Res Treat 172:69-82
Holmila, Reetta J; Vance, Stephen A; Chen, Xiaofei et al. (2018) Mitochondria-targeted Probes for Imaging Protein Sulfenylation. Sci Rep 8:6635
Rego, Stephen L; Harvey, Scott; Simpson, Sean R et al. (2018) TREX1 D18N mice fail to process erythroblast DNA resulting in inflammation and dysfunctional erythropoiesis. Autoimmunity :1-12
Li, X C; Wang, M Y; Yang, M et al. (2018) A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma. Ann Oncol 29:938-944
Godwin, Ryan C; Macnamara, Lindsay M; Alexander, Rebecca W et al. (2018) Structure and Dynamics of tRNAMet Containing Core Substitutions. ACS Omega 3:10668-10678
Lu, Yong; Wang, Qiang; Xue, Gang et al. (2018) Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors. Cancer Cell 33:1048-1060.e7
Akter, Salma; Fu, Ling; Jung, Youngeun et al. (2018) Chemical proteomics reveals new targets of cysteine sulfinic acid reductase. Nat Chem Biol 14:995-1004
Peak, Taylor C; Praharaj, Prakash P; Panigrahi, Gati K et al. (2018) Exosomes secreted by placental stem cells selectively inhibit growth of aggressive prostate cancer cells. Biochem Biophys Res Commun 499:1004-1010
Chmielewski, Jeffrey P; Bowlby, Sarah C; Wheeler, Frances B et al. (2018) CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD+ Pools. Mol Cancer Res 16:1687-1700
Han, Fei; Li, Chien-Feng; Cai, Zhen et al. (2018) The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance. Nat Commun 9:4728

Showing the most recent 10 out of 548 publications